Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.185
-0.065 (-2.89%)
At close: Apr 28, 2026, 4:00 PM EDT
2.190
+0.005 (0.23%)
After-hours: Apr 28, 2026, 4:01 PM EDT
Allogene Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Allogene Therapeutics stock have an average target of 8.35, with a low estimate of 3.85 and a high estimate of 14. The average target predicts an increase of 282.15% from the current stock price of 2.19.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Allogene Therapeutics stock from 15 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 6 |
| Buy | 6 | 6 | 6 | 6 | 6 | 7 |
| Hold | 1 | 1 | 0 | 0 | 0 | 2 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 12 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Sell → Hold Upgrades n/a | Sell → Hold | Upgrades | n/a | n/a | Apr 16, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +403.43% | Apr 16, 2026 |
| Jefferies | Jefferies | Strong Buy Maintains $6 → $10 | Strong Buy | Maintains | $6 → $10 | +357.67% | Apr 15, 2026 |
| Bernstein | Bernstein | Hold Maintains $1.6 → $3.85 | Hold | Maintains | $1.6 → $3.85 | +76.20% | Apr 14, 2026 |
| Argus Research | Argus Research | Hold Maintains $1.6 → $3.85 | Hold | Maintains | $1.6 → $3.85 | +76.20% | Apr 14, 2026 |
Financial Forecast
Revenue This Year
16.69K
Revenue Next Year
23.78M
from 16.69K
Increased by 142,416.42%
EPS This Year
-0.79
from -0.87
EPS Next Year
-0.78
from -0.79
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 105,000 | 147.2M | ||||||
| Avg | 16,687 | 23.8M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 882,133.1% | ||||||
| Avg | - | 142,416.4% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.56 | -0.44 | ||||||
| Avg | -0.79 | -0.78 | ||||||
| Low | -0.96 | -1.27 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.